

MBS Antibiogram 2023

GRAM NEGATIVE		ANTIBIOTICS														
1/1/2023-12/31/2023	Number tested	Amoxicillin/Clavulanic Acid	Ampicillin	Cefazolin	Cefepime	Ceftriaxone	Ciprofloxacin	Ertapenem	Gentamicin ^(b)	Levofloxacin	Meropenem	Nitrofurantoin	Piperacillin/Tazobactam	Tetracycline	Tobramycin ^(b)	Trimeth/Sulfa
ORGANISM	PERCENT SUSCEPTIBLE															
<i>Escherichia coli</i>	635	86	54	88	96	94	79	100	92	79	100	96	97	79	91	79
<i>Klebsiella pneumoniae</i>	63	92	0	88	95	89	89	100	98	90	100	19	99	79	93	89
<i>Proteus mirabilis</i>	67	73	53	81	89	84	63	100	82	63	97	0	100	0	85	55
<i>Pseudomonas aeruginosa</i> ^(b)	64				95		87			79	89		96		100	

GRAM POSITIVE		ANTIBIOTICS							
1/1/2023-12/31/2023	Number tested	Ampicillin	Clindamycin	Gentamycin (High-Level)	Linezolid	Nitrofurantoin	Oxacillin	Trimeth/Sulfa	Vancomycin
Organism	PERCENT SUSCEPTIBLE								
<i>Enterococcus faecalis</i>	63	98		83	99	98			95
<i>Staphylococcus aureus, ALL</i>	195		66		100		49	86	100
<i>MRSA only</i>	96		47		100		0	83	100
<i>MSSA only</i>	99		72		100		100	89	100
<i>Staphylococcus epidermidis</i>	31		38		100		32	49	100

85-100% Susceptible

60-84% Susceptible

<60% Susceptible

• Due to the presence of inducible beta-lactamases, this organism should be considered resistant to the antimicrobial indicated

Shaded boxes indicate organism/antimicrobial combines not tested routinely

Denotes manufacturer reporting limitation

(a) Data with fewer than 30 isolates has poor statistical validity.

(b) Aminoglycoside breakpoints lowered for Enterobacterales and *Pseudomonas aeruginosa* in 2023. Gentamicin is no longer a reliable treatment option for *Pseudomonas aeruginosa*.